Pancreatic Cancer Research

Clinical trialObservationalRecruiting

D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC

Department of Hepatobiliary Pancreatic Surgery, Fujian Provincial Hospital

Outcome
Ongoing
Phase
Observational
Status
Recruiting
Study type
Observational
Start
1 July 2024
Expected end
1 March 2027
Enrollment
37 participants
Sites
1
Primary outcomes
Objective response rate, ORR
Sponsor type
Academic / other
Results posted
No
Last update
26 June 2025

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This is a prospective, single-arm, multicenter, phase II trial to evaluate the efficacy and safety of D-TACE-HAIC (GEMOX protocol) in combination with Envafolimab and Lenvatinib for unresectable intrahepatic cholangiocarcinoma.